Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL TRANSDERMAL PATCHES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL TRANSDERMAL PATCHES MARKET: SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 MARKET GUIDE
2.2.4 APPLICATION POSITIONING GRID
2.2.5 COMPANY MARKET SHARE ANALYSIS
2.2.6 MULTIVARIATE MODELLING
2.2.7 TOP TO BOTTOM ANALYSIS
2.2.8 STANDARDS OF MEASUREMENT
2.2.9 VENDOR SHARE ANALYSIS
2.2.10 EPIDEMILOGY DATA
2.2.11 SALES VOLUME DATA
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL TRANSDERMAL PATCHES MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.2.1 CLASS I
11.2.2 CLASS II
11.2.3 CLASS III
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 REIMBURSEMENT FRAMEWORK
13 OPPUTUNITY MAP ANALYSIS
14 VALUE CHAIN ANALYSIS
15 HEALTHCARE ECONOMY
15.1 HEALTHCARE EXPENDITURE
15.2 CAPITAL EXPENDITURE
15.3 CAPEX TRENDS
15.4 CAPEX ALLOCATION
15.5 FUNDING SOURCES
15.6 INDUSTRY BENCHMARKS
15.7 GDP RATION IN OVERALL GDP
15.8 HEALTHCARE SYSTEM STRUCTURE
15.9 GOVERNMENT POLICIES
15.1 ECONOMIC DEVELOPMENT
16 GLOBAL TRANSDERMAL PATCHES MARKET, BY TYPE
16.1 OVERVIEW
16.2 DRUG IN-ADHASIVE
16.2.1 BY LAYER
16.2.1.1. SINGLE-LAYER DRUG-IN-ADHESIVE
16.2.1.1.1. BY DESING
16.2.1.1.1.1 RECTANGULAR
16.2.1.1.1.2 CIRCULAR
16.2.1.1.1.3 SQUARE
16.2.1.1.1.4 OTHERS
16.2.1.1.2. BY SIZE
16.2.1.1.2.1 12.5 CM2
16.2.1.1.2.2 18.75 CM2- 25 CM2
16.2.1.1.2.3 ABOVE 37.5 CM2
16.2.1.1.3. BY DOSE
16.2.1.1.3.1 5 MICROGRAM -70 MICROGRAM
16.2.1.1.3.2 70 MICROGRAM-20 MILIGRAM
16.2.1.1.3.3 20 MILIGRAM-30 MILIGRAM
16.2.1.1.3.4 ABOVE 30 MILIGRAM
16.2.1.2. MULTI-LAYER DRUG-IN-ADHESIVE
16.2.1.2.1. BY DESING
16.2.1.2.1.1 RECTANGULAR
16.2.1.2.1.2 CIRCULAR
16.2.1.2.1.3 SQUARE
16.2.1.2.1.4 OTHERS
16.2.1.2.2. BY SIZE
16.2.1.2.2.1 12.5 CM2
16.2.1.2.2.2 18.75 CM2- 25 CM2
16.2.1.2.2.3 ABOVE 37.5 CM2
16.2.1.2.3. BY DOSE
16.2.1.2.3.1 5 MICROGRAM -70 MICROGRAM
16.2.1.2.3.2 70 MICROGRAM-20 MILIGRAM
16.2.1.2.3.3 20 MILIGRAM-30 MILIGRAM
16.2.1.2.3.4 ABOVE 30 MILIGRAM
16.3 MATRIX
16.3.1 BY DESING
16.3.1.1. RECTANGULAR
16.3.1.2. CIRCULAR
16.3.1.3. SQUARE
16.3.1.4. OTHERS
16.3.2 BY SIZE
16.3.2.1. 12.5 CM2
16.3.2.2. 18.75 CM2- 25 CM2
16.3.2.3. ABOVE 37.5 CM2
16.3.3 BY DOSE
16.3.3.1. 5 MICROGRAM -70 MICROGRAM
16.3.3.2. 70 MICROGRAM-20 MILIGRAM
16.3.3.3. 20 MILIGRAM-30 MILIGRAM
16.3.3.4. ABOVE 30 MILIGRAM
16.4 RESERVOIR
16.4.1 BY DESING
16.4.1.1. RECTANGULAR
16.4.1.2. CIRCULAR
16.4.1.3. SQUARE
16.4.1.4. OTHERS
16.4.2 BY SIZE
16.4.2.1. 12.5 CM2
16.4.2.2. 18.75 CM2- 25 CM2
16.4.2.3. ABOVE 37.5 CM2
16.4.3 BY DOSE
16.4.3.1. 5 MICROGRAM -70 MICROGRAM
16.4.3.2. 70 MICROGRAM-20 MILIGRAM
16.4.3.3. 20 MILIGRAM-30 MILIGRAM
16.4.3.4. ABOVE 30 MILIGRAM
16.5 VAPOR PATCH
16.5.1 BY DESING
16.5.1.1. RECTANGULAR
16.5.1.2. CIRCULAR
16.5.1.3. SQUARE
16.5.1.4. OTHERS
16.5.2 BY SIZE
16.5.2.1. 12.5 CM2
16.5.2.2. 18.75 CM2- 25 CM2
16.5.2.3. ABOVE 37.5 CM2
16.5.3 BY DOSE
16.5.3.1. 5 MICROGRAM -70 MICROGRAM
16.5.3.2. 70 MICROGRAM-20 MILIGRAM
16.5.3.3. 20 MILIGRAM-30 MILIGRAM
16.5.3.4. ABOVE 30 MILIGRAM
16.6 OTHERS
17 GLOBAL TRANSDERMAL PATCHES MARKET, BY DELIVERY TYPE
17.1 OVERVIEW
17.2 PASSIVE DELIVERY SYSTEM
17.2.1 MATRIX DELIVERY SYSTEM
17.2.2 RESERVOIR DELIVERY SYSTEM
17.3 ACTIVE DELIVERY SYSTEM
17.3.1 STRUCTURE-BASED DRUG DELIVERY SYSTEM
17.3.2 ELECTRICALLY-BASED DRUG DELIVERY SYSTEM
17.3.2.1. IONTOPHORESIS
17.3.2.2. ELECTROPORATION
17.3.2.3. SONOPHORESIS
17.3.3 OTHERS
18 GLOBAL TRANSDERMAL PATCHES MARKET, BY DRUG TYPE
18.1 OVERVIEW
18.2 BRANDED
18.2.1 NDA
18.2.2 505(B)(2)
18.2.3 TRANSDERM SCOP
18.2.4 CLIMARA PRO
18.2.5 DURAGESIC
18.2.6 DAYTRANA
18.2.7 NEUPRO
18.2.8 EMSAM
18.2.9 MINIVELLE
18.2.10 VIVELLE-DOT
18.2.11 OTHERS
18.3 GENERIC
18.4 OTC PHARMACEUTICALS
19 GLOBAL TRANSDERMAL PATCHES MARKET, BY DRUG
19.1 OVERVIEW
19.2 SCOPOLAMINE
19.3 NITROGLYCERIN
19.4 BUPRENORPHINE
19.5 CLONIDINE
19.6 ESTRADIOL
19.7 FENTANYL
19.8 NICOTINE
19.9 TESTOSTERONE
19.1 LIDOCAINE
19.11 OXYBUTYNIN
19.12 METHYLPHENIDATE
19.13 SELEGILINE
19.14 RIVASTIGMINE
19.15 ROTIGOTINE
19.16 COMBINATION DRUGS
19.17 OTHERS
20 GLOBAL TRANSDERMAL PATCHES MARKET, BY APPLICATION
20.1 OVERVIEW
20.2 PAIN MANAGEMENT
20.2.1 ACUTE POSTOPERATIVE PAIN
20.2.2 POST-HERPETIC NEURALGIA PAIN
20.2.3 CHRONIC PAIN
20.2.4 OTHERS
20.3 NEUROLOGICAL DISORDER
20.3.1 PARKINSON'S DISEASE
20.3.2 MAJOR DEPRESSIVE DISORDER
20.3.3 DEMENTIA
20.3.4 OTHERS
20.4 ENDOCRINOLOGICAL DISORDERS
20.4.1 TESTOSTERONE DEFICIENCY
20.4.2 MENOPAUSAL SYMPTOMS
20.4.3 OTHERS
20.5 CARDIOVASCULAR DISEASES
20.5.1 ANGINA PECTORIS
20.5.2 HYPERTENSION
20.5.3 OTHERS
20.6 ONCOLOGY
20.7 DERMATOLOGY
20.8 SMOKING CESSATION
20.9 HYPERTENSION
20.1 MOTION SICKNESS
20.11 OVERACTIVE BLADDER
20.12 HORMONAL THERAPY/ DISORDERS
20.13 OTHERS
21 GLOBAL TRANSDERMAL PATCHES MARKET, BY MODE OF PURCHASE
21.1 OVERVIEW
21.2 PRESCRIPTION
21.3 OVER THE COUNTER
22 GLOBAL TRANSDERMAL PATCHES MARKET, BY TECHNOLOGY
22.1 OVERVIEW
22.2 ELECTRIC CURRENT
22.3 MECHANICAL ARRAYS
22.4 THERMAL ABLATION
22.5 CHEMICAL ENHANCER
22.6 OTHERS
23 GLOBAL TRANSDERMAL PATCHES MARKET, BY AGE GROUP
23.1 OVERVIEW
23.2 PEDIATRICS
23.3 ADULT
23.4 GERIATRICS
24 GLOBAL TRANSDERMAL PATCHES MARKET, BY END USERS
24.1 OVERVIEW
24.2 HOSPITAL
24.3 CLINICS
24.4 HOME HEALTHCARE
24.5 OTHERS
25 GLOBAL TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL
25.1 OVERVIEW
25.2 DIRECT TENDER
25.3 HOSPITALS PHARMACY
25.4 RETAIL PHARMACY
25.5 ONLINE PHARMACY
25.6 OTHERS
26 GLOBAL TRANSDERMAL PATCHES MARKET, BY GEOGRAPHY
26.1 GLOBAL TRANSDERMAL PATCHES MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
26.1.1 NORTH AMERICA
26.1.1.1. U.S.
26.1.1.2. CANADA
26.1.1.3. MEXICO
26.1.2 EUROPE
26.1.2.1. GERMANY
26.1.2.2. U.K.
26.1.2.3. FRANCE
26.1.2.4. ITALY
26.1.2.5. SPAIN
26.1.2.6. THE NETHERLANDS
26.1.2.7. SWITZERLAND
26.1.2.8. TURKEY
26.1.2.9. BELGIUM
26.1.2.10. RUSSIA
26.1.2.11. REST OF EUROPE
26.1.3 ASIA-PACIFIC
26.1.3.1. CHINA
26.1.3.2. JAPAN
26.1.3.3. SOUTH KOREA
26.1.3.4. INDIA
26.1.3.5. SINGAPORE
26.1.3.6. AUSTRALIA
26.1.3.7. MALAYSIA
26.1.3.8. PHILIPPINES
26.1.3.9. THAILAND
26.1.3.10. INDONESIA
26.1.3.11. REST OF ASIA-PACIFIC
26.1.4 SOUTH AMERICA
26.1.4.1. BRAZIL
26.1.4.2. ARGENTINA
26.1.4.3. REST OF SOUTH AMERICA
26.1.5 MIDDLE EAST AND AFRICA
26.1.5.1. SOUTH AFRICA
26.1.5.2. EGYPT
26.1.5.3. SAUDI ARABIA
26.1.5.4. U.A.E
26.1.5.5. ISRAEL
26.1.5.6. REST OF MIDDLE EAST AND AFRICA
26.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
27 GLOBAL TRANSDERMAL PATCHES MARKET, COMPANY LANDSCAPE
27.1 COMPANY SHARE ANALYSIS: GLOBAL
27.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
27.3 COMPANY SHARE ANALYSIS: EUROPE
27.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
27.5 MERGERS & ACQUISITIONS
27.6 NEW PRODUCT DEVELOPMENT & APPROVALS
27.7 EXPANSIONS
27.8 REGULATORY CHANGES
27.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
28 GLOBAL TRANSDERMAL PATCHES MARKET, SWOT AND DBMR ANALYSIS
29 GLOBAL TRANSDERMAL PATCHES MARKET, COMPANY PROFILE
29.1 POCONO PHARMACEUTICAL
29.1.1 COMPANY OVERVIEW
29.1.2 REVENUE ANALYSIS
29.1.3 GEOGRAPHIC PRESENCE
29.1.4 PRODUCT PORTFOLIO
29.1.5 RECENT DEVELOPEMENTS
29.2 HI TECH PRODUCTS
29.2.1 COMPANY OVERVIEW
29.2.2 REVENUE ANALYSIS
29.2.3 GEOGRAPHIC PRESENCE
29.2.4 PRODUCT PORTFOLIO
29.2.5 RECENT DEVELOPEMENTS
29.3 4P THERAPEUTICS (NUTRIBAND)
29.3.1 COMPANY OVERVIEW
29.3.2 REVENUE ANALYSIS
29.3.3 GEOGRAPHIC PRESENCE
29.3.4 PRODUCT PORTFOLIO
29.3.5 RECENT DEVELOPMENTS
29.4 TEIKOKU SEIYAKU CO., LTD.
29.4.1 COMPANY OVERVIEW
29.4.2 REVENUE ANALYSIS
29.4.3 GEOGRAPHIC PRESENCE
29.4.4 PRODUCT PORTFOLIO
29.4.5 RECENT DEVELOPEMENTS
29.5 JOHNSON & JOHNSON (PTY) LTD
29.5.1 COMPANY OVERVIEW
29.5.2 REVENUE ANALYSIS
29.5.3 GEOGRAPHIC PRESENCE
29.5.4 PRODUCT PORTFOLIO
29.5.5 RECENT DEVELOPEMENTS
29.6 PROSOLUS, INC.
29.6.1 COMPANY OVERVIEW
29.6.2 REVENUE ANALYSIS
29.6.3 GEOGRAPHIC PRESENCE
29.6.4 PRODUCT PORTFOLIO
29.6.5 RECENT DEVELOPEMENTS
29.7 LTS LOHMANN THERAPIE-SYSTEME AG
29.7.1 COMPANY OVERVIEW
29.7.2 REVENUE ANALYSIS
29.7.3 GEOGRAPHIC PRESENCE
29.7.4 PRODUCT PORTFOLIO
29.7.5 RECENT DEVELOPEMENTS
29.8 NOVEN PHARMACEUTICALS, INC. (HISAMITSU PHARMACEUTICAL CO., INC)
29.8.1 COMPANY OVERVIEW
29.8.2 REVENUE ANALYSIS
29.8.3 GEOGRAPHIC PRESENCE
29.8.4 PRODUCT PORTFOLIO
29.8.5 RECENT DEVELOPEMENTS
29.9 NITTO DENKO CORPORATION
29.9.1 COMPANY OVERVIEW
29.9.2 REVENUE ANALYSIS
29.9.3 GEOGRAPHIC PRESENCE
29.9.4 PRODUCT PORTFOLIO
29.9.5 RECENT DEVELOPEMENTS
29.1 CORIUM, LLC.
29.10.1 COMPANY OVERVIEW
29.10.2 REVENUE ANALYSIS
29.10.3 GEOGRAPHIC PRESENCE
29.10.4 PRODUCT PORTFOLIO
29.10.5 RECENT DEVELOPEMENTS
29.11 BAYER AG
29.11.1 COMPANY OVERVIEW
29.11.2 REVENUE ANALYSIS
29.11.3 GEOGRAPHIC PRESENCE
29.11.4 PRODUCT PORTFOLIO
29.11.5 RECENT DEVELOPEMENTS
29.12 MYLAN N.V (VIATRIS INC.)
29.12.1 COMPANY OVERVIEW
29.12.2 REVENUE ANALYSIS
29.12.3 GEOGRAPHIC PRESENCE
29.12.4 PRODUCT PORTFOLIO
29.12.5 RECENT DEVELOPEMENTS
29.13 ALZA CORPORATION (DISTRIBUTED BY- BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. )
29.13.1 COMPANY OVERVIEW
29.13.2 REVENUE ANALYSIS
29.13.3 GEOGRAPHIC PRESENCE
29.13.4 PRODUCT PORTFOLIO
29.13.5 RECENT DEVELOPEMENTS
29.14 ENDO INTERNATIONAL PLC
29.14.1 COMPANY OVERVIEW
29.14.2 REVENUE ANALYSIS
29.14.3 GEOGRAPHIC PRESENCE
29.14.4 PRODUCT PORTFOLIO
29.14.5 RECENT DEVELOPEMENTS
29.15 AMNEAL PHARMACEUTICALS LLC
29.15.1 COMPANY OVERVIEW
29.15.2 REVENUE ANALYSIS
29.15.3 GEOGRAPHIC PRESENCE
29.15.4 PRODUCT PORTFOLIO
29.15.5 RECENT DEVELOPEMENTS
29.16 SPARSHA PHARMA INTERNATIONAL PVT LTD
29.16.1 COMPANY OVERVIEW
29.16.2 REVENUE ANALYSIS
29.16.3 GEOGRAPHIC PRESENCE
29.16.4 PRODUCT PORTFOLIO
29.16.5 RECENT DEVELOPEMENTS
29.17 BIOTTS INC.
29.17.1 COMPANY OVERVIEW
29.17.2 REVENUE ANALYSIS
29.17.3 GEOGRAPHIC PRESENCE
29.17.4 PRODUCT PORTFOLIO
29.17.5 RECENT DEVELOPEMENTS
29.18 BLISS GVS PHARMA LIMITED
29.18.1 COMPANY OVERVIEW
29.18.2 REVENUE ANALYSIS
29.18.3 GEOGRAPHIC PRESENCE
29.18.4 PRODUCT PORTFOLIO
29.18.5 RECENT DEVELOPEMENTS
29.19 ACRUX LIMITED
29.19.1 COMPANY OVERVIEW
29.19.2 REVENUE ANALYSIS
29.19.3 GEOGRAPHIC PRESENCE
29.19.4 PRODUCT PORTFOLIO
29.19.5 RECENT DEVELOPEMENTS
29.2 ADHEXPHARMA
29.20.1 COMPANY OVERVIEW
29.20.2 REVENUE ANALYSIS
29.20.3 GEOGRAPHIC PRESENCE
29.20.4 PRODUCT PORTFOLIO
29.20.5 RECENT DEVELOPEMENTS
29.21 TESA TAPES (INDIA) PRIVATE LIMITED
29.21.1 COMPANY OVERVIEW
29.21.2 REVENUE ANALYSIS
29.21.3 GEOGRAPHIC PRESENCE
29.21.4 PRODUCT PORTFOLIO
29.21.5 RECENT DEVELOPEMENTS
29.22 MEDHERANT LIMITED.
29.22.1 COMPANY OVERVIEW
29.22.2 REVENUE ANALYSIS
29.22.3 GEOGRAPHIC PRESENCE
29.22.4 PRODUCT PORTFOLIO
29.22.5 RECENT DEVELOPEMENTS
29.23 UCB, INC.
29.23.1 COMPANY OVERVIEW
29.23.2 REVENUE ANALYSIS
29.23.3 GEOGRAPHIC PRESENCE
29.23.4 PRODUCT PORTFOLIO
29.23.5 RECENT DEVELOPEMENTS
29.24 LAVIPHARM
29.24.1 COMPANY OVERVIEW
29.24.2 REVENUE ANALYSIS
29.24.3 GEOGRAPHIC PRESENCE
29.24.4 PRODUCT PORTFOLIO
29.24.5 RECENT DEVELOPEMENTS
29.25 LEAD CHEMICAL CO.,LTD.
29.25.1 COMPANY OVERVIEW
29.25.2 REVENUE ANALYSIS
29.25.3 GEOGRAPHIC PRESENCE
29.25.4 PRODUCT PORTFOLIO
29.25.5 RECENT DEVELOPEMENTS
29.26 LUYE LIFE SCIENCES GROUP
29.26.1 COMPANY OVERVIEW
29.26.2 REVENUE ANALYSIS
29.26.3 GEOGRAPHIC PRESENCE
29.26.4 PRODUCT PORTFOLIO
29.26.5 RECENT DEVELOPEMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
30 RELATED REPORTS
31 CONCLUSION
32 QUESTIONNAIRE
33 ABOUT DATA BRIDGE MARKET RESEARCH
